Neurocritical Care News

Annexon Biosciences has announced positive topline results from a phase 3, randomized placebo-controlled clinical trial examining an investigational monoclonal antibody in those with Guillain-Barré syndrome.

The FDA has granted regenerative medicine advanced therapy designation for an investigational gene therapy to treat Huntington’s disease, according to the manufacturer.

The European Commission has granted marketing authorization under exceptional circumstances for Qalsody to treat those with amyotrophic lateral sclerosis associated with a mutation in the superoxide dismutase 1 gene.

The Alzheimer’s Drug Discovery Foundation has invested $5 million in Coya Therapeutics to help accelerate development and advance drugs to prevent, treat and cure Alzheimer’s disease and related dementias.

DENVER — For the glymphatic system of the brain to function properly, individuals must pay attention to their sleep duration, regulation and deprivation, according to a presenter at the American Academy of Neurology annual meeting.

DENVER — Early initiation of treatment with ofatumumab showed sustained benefit to those with treatment-naïve relapsing multiple sclerosis, Gabriel Pardo, MD, said in this Healio video from the American Academy of Neurology annual meeting.

According to statistics reported in a recent release from Sutter Health, up to 15% of strokes are suffered by individuals aged younger than 45 years, with incidence rising.

NEW YORK — New data suggests a link between inflammation during pregnancy and postpartum anxiety among women experiencing the highest anxiety symptoms, according to a poster at the American Psychiatric Association annual meeting.

The FDA has granted orphan drug designation to a small molecule therapeutic for individuals with Fragile X syndrome.

Enveric Biosciences announced it has signed a nonbinding term sheet to out-license a class of novel psilocin prodrugs to MindBio Therapeutics, an agreement that could yield more than $66 million in sales.